Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA.
FASEB J. 2010 Jul;24(7):2191-200. doi: 10.1096/fj.09-140368. Epub 2010 Feb 24.
SLC18A2 encodes the vesicular monoamine transporter 2 protein that regulates neurotransmission and reduces cytosolic toxicity of monoamines. Deletion of this gene causes lethality in mice, and DNA sequence variation in this gene is associated with alcoholism and Parkinson's disease, among other disorders. The Caucasian SLC18A2 promoter has at least 20 haplotypes (A-T), with A representing two-thirds of 1460 chromosomes. It is not known why A is selected in the human lineage. To understand the selection, here we took a functional approach by investigating the regulations of 4 representative haplotypes (A, C, G, and T) by 17 agents. We show that 76.5% of the agents were able to regulate A but only 11.8-23.5% of them regulated the 3 other infrequent ones, observing a positive correlation between haplotype frequency and regulatability. Pathway and molecular analyses revealed five signaling hubs that regulate the four haplotypes differentially, probably through targeting the polymorphic core promoter region. These findings suggest that greater diversity of transcriptional regulations is the driving force for the haplotype selection in SLC18A2.
SLC18A2 编码囊泡单胺转运体 2 蛋白,该蛋白调节神经递质传递并降低单胺的细胞溶质毒性。该基因的缺失会导致小鼠死亡,并且该基因的 DNA 序列变异与酒精中毒和帕金森病等疾病有关。白种人 SLC18A2 启动子至少有 20 种单倍型(A-T),其中 A 代表 1460 条染色体中的三分之二。目前尚不清楚为什么在人类谱系中选择了 A。为了了解选择的原因,我们通过研究 17 种药物对 4 种代表性单倍型(A、C、G 和 T)的调控,采用了一种功能方法。我们表明,76.5%的药物能够调节 A,但只有 11.8-23.5%的药物能够调节另外三种罕见的单倍型,观察到单倍型频率与可调节性之间存在正相关。通路和分子分析揭示了五个信号枢纽,它们通过靶向多态性核心启动子区域,差异调节这四个单倍型。这些发现表明,转录调控的更大多样性是 SLC18A2 中单倍型选择的驱动力。